Global Gastrointestinal Stromal Tumor Market Projected to Grow at 6.6% CAGR through 2026

A new insightful study titled “Global Market Study on Gastrointestinal Stromal Tumor: Stomach Indications to Account for Largest Revenue Share during 2017-2026” has recently been submitted to the repository of Market Research Reports Search Engine (MRRSE). According to the report, the global gastrointestinal stromal tumor market is projected to grow at 6.6% CAGR and reach nearly US$ 1.5 Bn in revenues.

Download Sample Copy in a PDF at- https://www.mrrse.com/sample/4291

According to the report, the global market is expected to grow on account of rising emphasis on early detection and effective treatment of gastrointestinal stromal tumors. Governments around the world are focusing on boosting their healthcare infrastructure, and emphasis on quality treatment has gained traction in recent years. Further, gastrointestinal stromal tumors are one of the most common types of mesenchymal tumors in the world, and this has further led to focus on developing effective treatment mechanisms. The report opines that a combination of macroeconomic and industry-specific factors will drive the growth of the market during the assessment period.

The study segments the global gastrointestinal stromal tumor market on the basis of indication, treatment type, end use and region. The indication segment is further sub-segmented into small intestine and stomach. By treatment type segment, the global market is categorized as surgery, radiation therapy, chemotherapy, targeted drug therapy and others. The end use segment divides the global market into specialized cancer treatment, clinics, hospitals and others. Geographically, the study divides the global market into key regions which are North America, Europe, Japan, Latin America, Asia Pacific Excluding Japan and Middle East and Africa.

On the basis of indication, the stomach segment accounts for higher revenue share. According to the report, this segment accounted for over 60% revenue share of the market in 2017. By end-use, hospitals continue to be one of the leading segment, accounting for over US$ 480 Mn in revenues by the end of the forecast period. By treatment type, chemotherapy accounts for the highest revenues, and is projected to grow at over 6% CAGR during the assessment period. Chemotherapy has been established as a more effective treatment option for gastrointestinal stromal tumors, and this is a key factor fuelling the growth.

The report also discusses the key strategies employed by the leading companies in the global gastrointestinal stromal market. Some of the key companies profiled in the report are Novartis AG, Pfizer Inc., NATCO Pharma Limited, Sun Pharmaceutical Industries Limited and Bayer Aktiengesellschaft.

Browse Full Global Gastrointestinal Stromal Tumor Market Report with TOC : https://www.mrrse.com/gastrointestinal-stromal-tumor-market

About (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact

State Tower
90, State Street Suite 700
Albany, NY – 12207 (United States)
Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/

This release was published on openPR.